C12N 2310/331
Universal or degenerate base
C12N2310/331 (Universal or degenerate base) appears on 81 US grants and 137 published applications in this corpus.
Search patents in C12N- Granted patents
- 81
- Published applications
- 137
- Assignees
- 49
- Inventors
- 174
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 4 |
| 2006 | 0 | 4 |
| 2007 | 0 | 7 |
| 2008 | 1 | 4 |
| 2009 | 4 | 7 |
| 2010 | 4 | 7 |
| 2011 | 1 | 8 |
| 2012 | 13 | 5 |
| 2013 | 2 | 10 |
| 2014 | 7 | 8 |
| 2015 | 4 | 14 |
| 2016 | 12 | 7 |
| 2017 | 3 | 6 |
| 2018 | 6 | 6 |
| 2019 | 2 | 3 |
| 2020 | 4 | 5 |
| 2021 | 6 | 7 |
| 2022 | 1 | 6 |
| 2023 | 2 | 6 |
| 2024 | 6 | 5 |
| 2025 | 0 | 5 |
| 2026 | 3 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Chemically modified guide RNAs for genome editing with Cas12b9 Jun 2026US 12,649,921 B2Verve Therapeutics, Inc.
- RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use27 Jan 2026US 12,534,728 B2Arrowhead Pharmaceuticals, Inc.
- RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)6 Jan 2026US 12,516,321 B2Sirna Therapeutics, Inc.
- Synthetic RIG-I-like receptor agonists22 Oct 2024US 12,123,003 B2Checkmate Pharmaceuticals, Inc.
- Base editing of ANGPTL3 and methods of using same for treatment of disease15 Oct 2024US 12,115,230 B2Verve Therapeutics, Inc.
- Conditionally activatable nucleic acid complexes12 Jun 2025US 2025/0188453 A1Switch Therapeutics Inc.
- Signal activatable nucleic acid constructs with wobble base pairings12 Jun 2025US 2025/0188454 A1Switch Therapeutics Inc.
- Base editing of angptl3 and methods of using same for treatment of disease15 May 2025US 2025/0152746 A1Verve Therapeutics, Inc.
- Multiple exon skipping compositions for dmd15 May 2025US 2025/0154507 A1Sarepta Therapeutics, Inc.
- RNAi Agents for Inhibiting Expression of PNPLA3, Pharmaceutical Compositions Thereof, and Methods of Use30 Jan 2025US 2025/0034577 A1Arrowhead Pharmaceuticals, Inc.
Most cited
By later US patents
- Methods and compositions for enhancing the efficacy and specificity of RNA silencing158US 7,750,144 B2University of Massachusetts · 2010
- Modulation of gene expression by oligomers targeted to chromosomal DNA128US 7,709,456 B2Board of Regents, The University of Texas System · 2010
- Oligomeric compounds for the modulation HIF-1α expression119US 7,737,264 B2Enzon Pharmaceuticals, Inc. · 2010
- Multiple exon skipping compositions for DMD95US 8,865,883 B2Sarepta Therapeutics, Inc. · 2014
- Methods and compositions for enhancing the efficacy and specificity of RNA silencing70US 8,309,705 B2University of Massachusetts · 2012